80 related articles for article (PubMed ID: 22535511)
1. In vivo application of chitosan to facilitate intestinal acyclovir absorption in rats.
Masuda A; Goto Y; Kurosaki Y; Aiba T
J Pharm Sci; 2012 Jul; 101(7):2449-56. PubMed ID: 22535511
[TBL] [Abstract][Full Text] [Related]
2. β-cyclodextrin chitosan-based hydrogels with tunable pH-responsive properties for controlled release of acyclovir: design, characterization, safety, and pharmacokinetic evaluation.
Malik NS; Ahmad M; Alqahtani MS; Mahmood A; Barkat K; Khan MT; Tulain UR; Rashid A
Drug Deliv; 2021 Dec; 28(1):1093-1108. PubMed ID: 34114907
[TBL] [Abstract][Full Text] [Related]
3. The effect of chitosan on the bioaccessibility and intestinal permeability of acyclovir.
Kubbinga M; Augustijns P; García MA; Heinen C; Wortelboer HM; Verwei M; Langguth P
Eur J Pharm Biopharm; 2019 Mar; 136():147-155. PubMed ID: 30682491
[TBL] [Abstract][Full Text] [Related]
4. Effect of chitosan glutamate, carbomer 974P, and EDTA on the in vitro Caco-2 permeability and oral pharmacokinetic profile of acyclovir in rats.
Merzlikine A; Rotter C; Rago B; Poe J; Christoffersen C; Thomas VH; Troutman M; El-Kattan A
Drug Dev Ind Pharm; 2009 Sep; 35(9):1082-91. PubMed ID: 19294548
[TBL] [Abstract][Full Text] [Related]
5. Utilization of nanotechnology to enhance percutaneous absorption of acyclovir in the treatment of herpes simplex viral infections.
Al-Subaie MM; Hosny KM; El-Say KM; Ahmed TA; Aljaeid BM
Int J Nanomedicine; 2015; 10():3973-85. PubMed ID: 26109856
[TBL] [Abstract][Full Text] [Related]
6. Nano and microparticulate chitosan-based systems for antiviral topical delivery.
Calderón L; Harris R; Cordoba-Diaz M; Elorza M; Elorza B; Lenoir J; Adriaens E; Remon JP; Heras A; Cordoba-Diaz D
Eur J Pharm Sci; 2013 Jan; 48(1-2):216-22. PubMed ID: 23159663
[TBL] [Abstract][Full Text] [Related]
7. Formulation of acyclovir-loaded solid lipid nanoparticles: 2. Brain targeting and pharmacokinetic study.
El-Gizawy SA; El-Maghraby GM; Hedaya AA
Pharm Dev Technol; 2019 Dec; 24(10):1299-1307. PubMed ID: 31507245
[TBL] [Abstract][Full Text] [Related]
8. Mucoadhesive microspheres for gastroretentive delivery of acyclovir: in vitro and in vivo evaluation.
Dhaliwal S; Jain S; Singh HP; Tiwary AK
AAPS J; 2008 Jun; 10(2):322-30. PubMed ID: 18523891
[TBL] [Abstract][Full Text] [Related]
9. In vitro percutaneous penetration of acyclovir from solvent systems and Carbopol 971-P hydrogels: influence of propylene glycol.
Díez-Sales O; Garrigues TM; Herráez JV; Belda R; Martín-Villodre A; Herráez M
J Pharm Sci; 2005 May; 94(5):1039-47. PubMed ID: 15793815
[TBL] [Abstract][Full Text] [Related]
10. Comparison of liposome-encapsulated acyclovir with acyclovir ointment: ocular pharmacokinetics in rabbits.
Chetoni P; Rossi S; Burgalassi S; Monti D; Mariotti S; Saettone MF
J Ocul Pharmacol Ther; 2004 Apr; 20(2):169-77. PubMed ID: 15117573
[TBL] [Abstract][Full Text] [Related]
11. Development of mucoadhesive floating hollow beads of acyclovir with gastroretentive properties.
Svirskis D; Seyfoddin A; Chalabi S; In Kim JH; Langford C; Painter S; Al-Kassas R
Pharm Dev Technol; 2014 Aug; 19(5):571-6. PubMed ID: 23859639
[TBL] [Abstract][Full Text] [Related]
12. PEGylated Lipid Polymeric Nanoparticle-Encapsulated Acyclovir for In Vitro Controlled Release and Ex Vivo Gut Sac Permeation.
Mahmood S; Kiong KC; Tham CS; Chien TC; Hilles AR; Venugopal JR
AAPS PharmSciTech; 2020 Oct; 21(7):285. PubMed ID: 33057878
[TBL] [Abstract][Full Text] [Related]
13. Effect of chitosan, benzalkonium chloride and ethylenediaminetetraacetic acid on permeation of acyclovir across isolated rabbit cornea.
Majumdar S; Hippalgaonkar K; Repka MA
Int J Pharm; 2008 Feb; 348(1-2):175-8. PubMed ID: 17897799
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of novel dipeptide ester prodrugs of acyclovir after oral administration: intestinal absorption and liver metabolism.
Anand BS; Katragadda S; Mitra AK
J Pharmacol Exp Ther; 2004 Nov; 311(2):659-67. PubMed ID: 15226381
[TBL] [Abstract][Full Text] [Related]
15. Acyclovir-containing liposomes for potential ocular delivery. Corneal penetration and absorption.
Law SL; Huang KJ; Chiang CH
J Control Release; 2000 Jan; 63(1-2):135-40. PubMed ID: 10640587
[TBL] [Abstract][Full Text] [Related]
16. Development of mucoadhesive microspheres of acyclovir with enhanced bioavailability.
Tao Y; Lu Y; Sun Y; Gu B; Lu W; Pan J
Int J Pharm; 2009 Aug; 378(1-2):30-6. PubMed ID: 19465102
[TBL] [Abstract][Full Text] [Related]
17. Acyclovir delivery matrices based on poly(ethylene glycol)/chitosan semi-interpenetrating networks.
Diez-Sales O; Dolz M; Hernandez MJ; Casanovas A; Herraez M
J Pharm Sci; 2007 Jun; 96(6):1653-7. PubMed ID: 17286301
[TBL] [Abstract][Full Text] [Related]
18. Development and characterization of sponge-like acyclovir ocular minitablets.
Refai H; Tag R
Drug Deliv; 2011 Jan; 18(1):38-45. PubMed ID: 20804440
[TBL] [Abstract][Full Text] [Related]
19. [Preparation of hepatic targeting antivirus agent NGA-ACV and its targeting property].
Fan JZ; Li TL; Pang QJ; Guan CT; He Y; Su KY
Yao Xue Xue Bao; 1996; 31(8):585-90. PubMed ID: 9772705
[TBL] [Abstract][Full Text] [Related]
20. Topical delivery of different acyclovir palmitate liposome formulations through rat skin in vitro.
Liu H; Pan WS; Tang R; Luo SD
Pharmazie; 2004 Mar; 59(3):203-6. PubMed ID: 15074594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
